Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses
Section snippets
Transthyretin aggregation appears to cause the transthyretin amyloidoses
The TTR amyloid diseases (amyloidoses) appear to be caused by extracellular TTR tetramer dissociation, monomer misfolding and misassembly into a variety of aggregate morphologies [1, 2, 3•] (Figure 1). The field has hypothesized that oligomers formed during the process of amyloidogenesis lead to cellular toxicity [4, 5]. The displacement of tissue by extracellular amyloid is also thought to exacerbate pathology [6]. The TTR amyloidoses include senile systemic amyloidosis (SSA), familial amyloid
Transthyretin's thyroxine binding sites
Each T4 binding site is characterized by a series of subsites [15•] (Figure 3D), an outer binding subsite, an inner binding subsite, and an intervening interface that are all composed of pairs of symmetric hydrophobic depressions referred to as halogen binding pockets (HBPs), wherein the iodine atoms of T4 reside (Figure 3B) [16]. HBPs 1 and 1′ in the outer binding subsite comprise the side chains of Ala108/108′, Thr106/106′, Met13/13′ and Lys15/15′ with the pocket lined by methyl and methylene
Small molecule TTR ligands and the basis for kinetic stabilization
Over one thousand aromatic small molecules exhibiting structural complementarity to the T4 binding sites within TTR have been synthesized [18, 19, 20, 21, 22, 23, 24, 25, 26••, 27••, 28••, 29, 30] and are typically composed of two aromatic rings occupying the inner and outer T4 binding subsites (Figure 3D). The aromatic rings composing TTR kinetic stabilizers can either be linked directly (e.g. biphenyls) [19, 20] or tethered through short hydrophobic linkers [26••, 27••] (Figure 3D). Most of
Structure-based design of TTR kinetic stabilizers
Kinetic stabilizers for the treatment of the TTR amyloidoses must be both highly potent and selective. The ligands must not interact with the thyroid hormone receptor (THR), a major concern given the similarity of some kinetic stabilizers with triiodothyronine (T3, the primary thyroid hormone) and T4 (the prohormone). Nonsteroidal anti-inflammatory drug (NSAID) activity is also contraindicated for treating TTR amyloidosis patients; thus, TTR kinetic stabilizers should exhibit minimal NSAID
Optimal aryl-X ring substructures
To optimize the aryl-X ring, a library of 2-arylbenzoxazoles was synthesized in which the benzoxazole ring was purposefully unmodified and the 2-aryl ring was systematically substituted (Figure 4A). The library members were evaluated for TTR amyloid inhibition potency, plasma TTR binding selectivity, as well as undesired COX-1 and THR binding activity (Appendix A, Table S4). Substituents at the 3 and 4 positions and, especially, the 3, 4 and 5 positions afforded the most potent and selective
Optimal linker substructures
We next evaluated possible substructures to link the aryls occupying the inner and outer TTR T4 binding subsites, including CHCH, –CH2CH2–, polar 1–3 atom linkers and fused five-membered ring heteroaromatic linkers. One aromatic ring is always unsubstituted in analogues made for this purpose, whilst the other ring comprises a 3,5-X2 or a 3,5-X2-4-hydroxyphenyl substructure, where X is Br or Me (Figure 4B and Appendix A, Table S5). Analysis of the numerous TTR•(ligand)2 structures in the Protein
Optimal aryl-Z ring substructures
Evaluation of aryl-Z ring candidates was carried out using a library composed of a fixed aryl-X substructure (N-(3,5-dibromo-4-hydroxyphenyl) as well as a fixed and suboptimal amide linker (Figure 4C) [28••]. Regardless of the diverse range of aryl-Z substituents evaluated, most were capable of increasing inhibitor potency and plasma TTR binding selectivity (Appendix A, Table S7). Independent of the substituent, 2,6-substituents are generally more potent and selective than 2,5-substituents that
Substructure combination strategy is effective
Using SAR data from the aryl-X, aryl-Z and linker-Y substructure optimization studies [26••, 27••, 28••], we envisioned that a library rich in highly potent and selective TTR kinetic stabilizers could be generated by simply combining the most highly ranked substructures. As a demonstration, we utilized the highly ranked 3,5-dibromo-4-hydroxyphenyl aryl-X ring (and isosteric variants replacing the OH functional group with a NH2), a variety of highly ranked aryl-Z rings and two hydrophobic
Conclusions
The systematic optimization of the three substructures comprising a typical TTR kinetic stabilizer has enabled rank ordering of these substructural components and these data now enable us to confidently predict the structures of diverse, potent and highly selective TTR kinetic stabilizers that inhibit TTR amyloidogenesis in vivo. From the high-resolution X-ray crystallographic data, we now know why some aryls prefer the inner binding subsite and others prefer the outer binding subsite. We also
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
We are grateful to the NIH (DK46335 to JWK and AI42266 to IAW), as well as the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation for long standing financial support. The progress outlined within would not have been possible without the hard work, determination, and creativity of numerous co-workers cited within, including those who co-authored this review.
References (66)
- et al.
Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid
Adv Protein Chem
(1997) - et al.
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans
N Engl J Med
(1997) - et al.
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis
Biochemistry
(2008) - et al.
A comparative analysis of 23 structures of the amyloidogenic protein transthyretin
J Mol Biol
(2000) - et al.
Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-l-thyronine at 2.2 Å resolution
Acta Crystallogr D Biol Crystallogr
(1996) - et al.
Synthesis and evaluation of biaryl amines and benzylamines as inhibitors of TTR amyloid fibril formation
- et al.
Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis. Inhibitors using biochemical and structural studies
J Med Chem
(2009) - et al.
Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
Proc Natl Acad Sci U S A
(1998) - et al.
The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin ‘amyloid-like’ oligomer leading to disaggregation
Biochem J
(2000) - et al.
Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 A resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites
Acta Crystallogr D Biol Crystallogr
(2001)
Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors
Bioorg Med Chem Lett
Iodination of salicylic acid improves its binding to transthyretin
Biochim Biophys Acta, Proteins Proteomics
The binding of xanthone derivatives to transthyretin
Biochem Pharmacol
Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative
Biochem J
Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors
Bioorg Med Chem Lett
Binding of thyroid hormones and analogs to the human plasma protein prealbumin
Biochemistry
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Biochemistry
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses
Acc Chem Res
Abeta oligomers—a decade of discovery
J Neurochem
Neurodegenerative disease: amyloid pores from pathogenic mutations
Nature
Amyloidosis
Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin
Biochem Biophys Res Commun
Prevention of transthyretin amyloid disease by changing protein misfolding energetics
Science
A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119
J Rheumatol
Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å
J Mol Biol
Structure of human plasma prealbumin at 2–5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding
J Mol Biol
Therapeutic strategies for human amyloid diseases
Nat Rev Drug Discov
Mechanisms of molecular recognition: crystal structure analysis of human and rat transthyretin inhibitor complexes
Clin Chem Lab Med
Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation
J Med Chem
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity
Chem Biol
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action
Angew Chem Int Ed Engl
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis
J Med Chem
Rational design of potent human transthyretin amyloid disease inhibitors
Nat Struct Biol
Cited by (160)
Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis
2023, Current Opinion in Chemical BiologyClusterin in Alzheimer's disease: An amyloidogenic inhibitor of amyloid formation?
2022, Biochimica et Biophysica Acta - Molecular Basis of DiseaseSynthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors
2022, Bioorganic and Medicinal ChemistryCitation Excerpt :Over 100 TTR mutants have been identified in various populations worldwide, and the majority of these are associated with amyloidogenesis and diseases. Pathogenic TTR variants are implicated in familial amyloid polyneuropathy (e.g., V30M and L55P) and familial amyloid cardiomyopathy (e.g., V122I) characterized by tissue-selective deposition of TTR in the peripheral nerves and heart, respectively.7,9,11–16 Considerable effort has been invested in identifying small molecules called pharmacological chaperones that bind to the two hydrophobic T4-binding pockets at the unique dimer − dimer interface.
Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis
2022, Biophysical ChemistryCitation Excerpt :The native states of these amyloid precursor proteins are structurally and functionally diverse [1,2,5,20] ranging from well-folded globular proteins (e.g. insulin, lysozyme, transthyretin, immunoglobulin (Ig) domains) to molten-globular proteins (lipid-free apolipoproteins apoA-I, apoA-II and apoE) and intrinsically disordered proteins (IDPs) and peptides (serum amyloid A (SAA), α-synuclein, amylin, Alzheimer's amyloid-beta (Aβ) peptide). Some of these proteins undergo a thermodynamically reversible unfolding (lysosome, SAA, lipid-free apolipoproteins), while others are stabilized by kinetic barriers (Ig light chain, transthyretin, lipid-bound apolipoproteins) [21–25]. Well-ordered regions in the native states of these proteins can be rich in the β-sheet (Ig LC, transthyretin), α-helix (apolipoproteins, SAA), or a combination thereof (lysozyme, insulin).
Mechanisms of amyloid proteins aggregation and their inhibition by antibodies, small molecule inhibitors, nano-particles and nano-bodies
2021, International Journal of Biological MacromoleculesIntrinsically disordered proteins and biomolecular condensates as drug targets
2021, Current Opinion in Chemical Biology